Validation of highly sensitive flow cytometry as a biomarker for rituximab in SLE: a rationale for more intensive treatment to improve clinical ouctomes - Yusof, MYMd; Shaw, D; Rawstron, A (Ann Rheum Dis, 2016)
et al.